Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 60

1.

NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.

Di Pilato M, Mejías-Pérez E, Zonca M, Perdiguero B, Gómez CE, Trakala M, Nieto J, Nájera JL, S Sorzano CO, Combadière C, Pantaleo G, Planelles L, Esteban M.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1333-42. doi: 10.1073/pnas.1424341112. Epub 2015 Mar 4.

PMID:
25739961
2.

Opsin expression in human epidermal skin.

Haltaufderhyde K, Ozdeslik RN, Wicks NL, Najera JA, Oancea E.

Photochem Photobiol. 2015 Jan-Feb;91(1):117-23. doi: 10.1111/php.12354. Epub 2014 Nov 13.

3.

UV light activates a Gαq/11-coupled phototransduction pathway in human melanocytes.

Bellono NW, Najera JA, Oancea E.

J Gen Physiol. 2014 Feb;143(2):203-14. doi: 10.1085/jgp.201311094.

4.

Management of Thrombotic Thrombocytopenic Purpura with Autoantibodies to ADAMTS-13 and Concurrent Preeclampsia in Pregnancy: Multidisciplinary Team Approach.

Patrick T, Carlan SJ, Najera JE, Eastwood J.

AJP Rep. 2012 Nov;2(1):37-8. doi: 10.1055/s-0032-1305799. Epub 2012 Feb 22.

5.

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.

Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M.

PLoS One. 2012;7(10):e48524. doi: 10.1371/journal.pone.0048524. Epub 2012 Oct 31.

6.

Akinetic mutism-a serious complication to tacrolimus-based GVHD prophylaxis.

Najera JE, Alousi A, De Lima M, Ciurea SO.

Bone Marrow Transplant. 2013 Jan;48(1):157-8. doi: 10.1038/bmt.2012.110. Epub 2012 Jun 18. No abstract available.

PMID:
22705799
7.

Chronic eosinophilic leukemia presenting with mouth and penile ulcers.

Najera JE, Harn L.

Am J Med. 2012 Aug;125(8):e5-6. doi: 10.1016/j.amjmed.2011.11.017. Epub 2012 Jun 7. No abstract available.

PMID:
22681908
8.

Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.

Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, Esteban M.

J Virol. 2012 May;86(9):5026-38. doi: 10.1128/JVI.06684-11. Epub 2012 Mar 14.

9.

UVA phototransduction drives early melanin synthesis in human melanocytes.

Wicks NL, Chan JW, Najera JA, Ciriello JM, Oancea E.

Curr Biol. 2011 Nov 22;21(22):1906-11. doi: 10.1016/j.cub.2011.09.047. Epub 2011 Nov 3.

10.

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.

García-Arriaza J, Nájera JL, Gómez CE, Tewabe N, Sorzano CO, Calandra T, Roger T, Esteban M.

PLoS One. 2011;6(8):e24244. doi: 10.1371/journal.pone.0024244. Epub 2011 Aug 31.

11.

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, García-Arriaza J, Guardo AC, Pérez I, Díaz-Brito V, Conde MS, González N, Alvarez A, Alcamí J, Jiménez JL, Pich J, Arnaiz JA, Maleno MJ, León A, Muñoz-Fernández MA, Liljeström P, Weber J, Pantaleo G, Gatell JM, Plana M, Esteban M.

Vaccine. 2011 Oct 26;29(46):8309-16. doi: 10.1016/j.vaccine.2011.08.098. Epub 2011 Sep 9.

PMID:
21907749
12.

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.

Gómez CE, Nájera JL, Perdiguero B, García-Arriaza J, Sorzano CO, Jiménez V, González-Sanz R, Jiménez JL, Muñoz-Fernández MA, López Bernaldo de Quirós JC, Guardo AC, García F, Gatell JM, Plana M, Esteban M.

J Virol. 2011 Nov;85(21):11468-78. doi: 10.1128/JVI.05165-11. Epub 2011 Aug 24.

13.

MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

Gómez CE, Nájera JL, Krupa M, Perdiguero B, Esteban M.

Curr Gene Ther. 2011 Jun;11(3):189-217. Review.

PMID:
21453284
14.

T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations.

Mónaco DC, Rodríguez AM, Pascutti MF, Carobene M, Falivene J, Gómez A, Maeto C, Turk G, Nájera JL, Esteban M, Gherardi MM.

PLoS One. 2011 Feb 18;6(2):e17185. doi: 10.1371/journal.pone.0017185.

15.

Diversity in viral anti-PKR mechanisms: a remarkable case of evolutionary convergence.

Domingo-Gil E, Toribio R, Nájera JL, Esteban M, Ventoso I.

PLoS One. 2011 Feb 2;6(2):e16711. doi: 10.1371/journal.pone.0016711.

16.

A research agenda for malaria eradication: vector control.

malERA Consultative Group on Vector Control.

PLoS Med. 2011 Jan 25;8(1):e1000401. doi: 10.1371/journal.pmed.1000401. Review.

17.

Some lessons for the future from the Global Malaria Eradication Programme (1955-1969).

Nájera JA, González-Silva M, Alonso PL.

PLoS Med. 2011 Jan 25;8(1):e1000412. doi: 10.1371/journal.pmed.1000412. Review.

18.

A research agenda for malaria eradication: drugs.

malERA Consultative Group on Drugs.

PLoS Med. 2011 Jan 25;8(1):e1000402. doi: 10.1371/journal.pmed.1000402. Review.

19.

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation.

AIDS. 2011 Mar 13;25(5):679-89. doi: 10.1097/QAD.0b013e328342ff93.

20.

Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.

Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M.

Vaccine. 2011 Feb 4;29(7):1504-13. doi: 10.1016/j.vaccine.2010.12.016. Epub 2010 Dec 21.

PMID:
21182993
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk